Federico Pirro

Federico Pirro

Auto-generated profile, based on publicly available information

Federico Pirro

Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2021 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
FPFederico Pirro
Federico Pirro
GCGiacomo Caldarola
Giacomo Caldarola
ACAndrea Chiricozzi
Andrea Chiricozzi
MBMartina Burlando
Martina Burlando
MMMarco Mariani
Marco Mariani
CSClara De Simone
Clara De Simone
Background The efficacy of biological therapies used for the treatment of chronic plaque psoriasis can be influenced by numerous variables including body mass index (BMI). Objective This study aimed to evaluate the impact of BMI on the short-term and long-term efficacy of biological therapies in clinical practice and to identify the best therapeutic options in obese patients (BMI ≥ 30 kg/m2). Methods A multicentric retrospective study was conducted in patients who initiated a biological therapy during the period January 2006–December 2019. The proportion of patients achieving a 90% improvement of baseline Psoriasis Area and Severity Index at weeks 12 and 24 was calculated also recording the 12- and 24-month drug survival as a measure of long-term efficacy, performing multivariate analyses to assess the impact of different variables. Results Five hundred and four patients with psoriasis were included. After 12 and 24 weeks, the proportion of patients achieving a 90% improvement of baseline Psoriasis Area and Severity Index response was higher in patients with a BMI < 30 kg/m2 compared with those with a BMI ≥ 30 kg/m2 [54.90% vs 43.45% (p = 0.014) at week 12 and 66.84% vs 56.55% (p = 0.021) at week 24]. The Kaplan–Meier survival curves showed how obese patients had a higher probability of discontinuation due to a lack or loss of efficacy (p = 0.0192) compared with non-obese patients. The drug survival analysis also showed that BMI negatively affected the drug survival of secukinumab (odds ratio 1.27, p < 0.001) and ustekinumab (odds ratio 1.06, p = 0.050), while the long-term efficacy of adalimumab, etanercept, and ixekizumab was not influenced by BMI. Conclusions Obesity (BMI ≥ 30 kg/m2) negatively affects the clinical response of biological drugs in psoriatic patients, with anti-interleukin drugs being more affected by BMI than anti-tumor necrosis factor drugs.

17 February 2020 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
GCGiacomo Caldarola
Giacomo Caldarola
FPF. Pirro
F. Pirro
ASA. Di Stefani
A. Di Stefani
MTMarina Talamonti
Marina Talamonti
MGMarco Galluzzo
Marco Galluzzo
CSC. De Simone
C. De Simone
Background: Real life data often highlight side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective. To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants. Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3-4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis. Keywords: psoriasis, IL17, secukinumab, ixekizumab, anti IL17, side effects, eczematous reactions

28 June 2021 in Expert Opinion on Biological Therapy
Verified
Journal Article
Open access
MGMarco Galluzzo
Marco Galluzzo
GCGiacomo Caldarola
Giacomo Caldarola
CSC De Simone
C De Simone
NBN Bernardini
N Bernardini
GMGaia Moretta
Gaia Moretta
KPKetty Peris
Ketty Peris
Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks. Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.

19 June 2019 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
NGNiccolò Gori
Niccolò Gori
GCGiacomo Caldarola
Giacomo Caldarola
FPFederico Pirro
Federico Pirro
CSClara De Simone
Clara De Simone
KPKetty Peris
Ketty Peris

12 February 2019 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
FPFederico Pirro
Federico Pirro
GCGiacomo Caldarola
Giacomo Caldarola
CSClara De Simone
Clara De Simone
GMGaia Moretta
Gaia Moretta
GGGiulia Giovanardi
Giulia Giovanardi
KPKetty Peris
Ketty Peris

16 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GPGiovanni Pellacani
Giovanni Pellacani
LBLaura Bigi
Laura Bigi
APaurora parodi
aurora parodi
MBMartina Burlando
Martina Burlando
CLCaterina Lanna
Caterina Lanna
KPKetty Peris
Ketty Peris
This open-label multicentre trial evaluated the efficacy and safety of oral dimethyl fumarate (DMF) in patients with moderate-to-severe plaque psoriasis in real-life clinical practice over 52 weeks. Disease severity and improvement were assessed using the psoriasis area severity index (PASI), body surface area (BSA) affected, and Physician Global Assessment (PGA). Quality of life (QoL) was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. The visual analogue scale (VAS) was used to quantify pruritus and measure treatment satisfaction. A total of 141 patients were included, being 66.7% male, aged 49.1 ± 14.7 years and with disease duration of 16 ± 12.1 years. After 52 weeks, mean PASI decreased from 15.9 ± 6.8 to 1.5 ± 2 and 87.7%, 56.9% and 24.6% of patients achieved PASI 75/90/100 response, respectively. BSA decreased from 26.5 ± 14.8% to 2.7 ± 3.5% at 52 weeks, and 81.5% of patients had a PGA 0-1. DLQI scores decreased from 9.4 ± 6.4 to 2.1 ± 3.3, and VAS of pruritus decreased from 53 ± 28.4 to 19.1 ± 26.2 at Week 52. VAS for treatment satisfaction was 79.4 ± 29.4 at Week 52. A total of 34.2% of patients had an AE leading to permanent discontinuation. These findings show that DMF can significantly improve indices of disease severity, pruritus and QoL, with high levels of patient satisfaction and similar safety profile to other fumarates.